Cachexia, commonly seen in cancer patients, is not simply caused by malnutrition due to anorexia. It is a more complex condition including reduced intake, metabolic dysfunction, and increased energy requirement. This process involves a va riety of inflammatory cytokines in cancer cells, alterations in protein and lipid metabolism, and an imbalance in the pro duction and degradation processes of muscle proteins.
INTRODUCTION
Nutritional problems are often encountered during the treat ment of cancer. A prospective observational study reported that 51.1% of all cancer patients presented nutritional impair ment, and 64% of patients showed reduction in weight 6 months after diagnosis. 1 Weight loss, especially cachexia, are widely recognized as not only reduced physical function and quality of life, but also poor prognostic factors in cancer patients. Clas sically, BMI is often used for measuring nutritional status of a patient, and recent studies have focused more on sarcopenia. 2 However, nutritional problems are complex and vary depend ing on the location and stage of cancer. 1, 3 Therefore, nutritional support for cancer patients should be based on the assessment of each patient' s condition and appropriate planning of the outcome. In this review, we will look at what should be consid www.irjournal.org reduced muscle loss in tumorbearing rats. 6, 7 Although it is controversial if TNFα levels in blood are higher in cancer pa tients, it is believed that TNFα activates nuclear factor kappa lightchainenhancer of activated B cells (NFκB) and pro motes the degradation of proteins through a pathway inde pendent of the ubiquitinproteasome pathway. 8 Furthermore, TNFα activates other cytokines and can cause symptoms as sociated with cachexia, such as anorexia. 9 A study using an anti TNFα agent, etanercept, in cancer patients reported that etan ercept improved chemotherapy adherence and fatigue during cancer treatment. 10 IL6 is also believed to play a very impor tant role in cancerrelated cachexia. In a study using ApcMin/+ mice, elevation of IL6 did not induce cachexia in the tumorfree mice. However, elevation of IL6 was associated with decreased skeletal muscle and fat mass, and increased tumor burden in ApcMin/+ mice. 11 In cancer patients, IL6 increases the acute phase reactants such as CRP through signal transducer and activator of transcription 3 (STAT3), and it is associated with muscle wasting. 12 However, in a study of lung cancer patients, administration of humanized antiIL6 antibody was effective in alleviating symptoms such as anorexia, but it did not induce weight gain. 13 Therefore, it is observed that cancerassociated cachexia is not simply related to one cytokine, but is influ enced by the interactions of various signaling substances.
In catabolic diseases, various hormones and cytokines regu late protein production and degradation through the ubiqui tinproteasome pathway, autophagy, and transforming growth factor beta family ligands. Upregulation of the ubiquitinpro teasome pathway by catabolic stress in several animal tumor models has been associated with muscle wasting. Myofibrillar components of muscle protein are mainly disintegrated in the ubiquitinproteasome pathway, and this leads to decreased muscle strength. 14 Moreover, the stress hormones and inflam matory cytokines promote autophagy and mitochondrial dys function, which lead to muscle atrophy. These processes are regulated by atrogenes and transcription factors, such as NF κB and forkhead box protein O (FOXO). 14 Especially in cancer patients, chemotherapy itself and malabsorption by complica tions of chemotherapy, such as mucositis, can directly induce muscle wasting. 15 It is well known that impairment of carbohydrate metabo lism occurs in cancer patients. Cancer cells show high glycoly sis, and glucose is produced by gluconeogenesis in the liver using lactate produced by the cancer cells. 16 During canceras sociated cachexia, increased level of insulinlike growth fac tor1 is observed, resulting in insulin resistance. 17 Thus, most of the glucose induced is used by the cancer cells; hence, can cer patients have a very high energy demand. However, in ac tual clinical studies, insulin resistance is not inevitably associ ated with weight loss. 18 Lipid metabolism is also impaired in cancer patients. The loss of adipose tissue by metabolic impairment further pro motes cancerassociated cachexia. The accumulation of tri glycerides in the cytoplasm of adipocytes is the most efficient method of energy storage. Free fatty acid and glycerol from tri glyceride increase in patients with cancerassociated cachex ia. 19 Higher lipolysis and fat oxidation rates were observed in cancer patients losing weight as compared to that of healthy control. 20 This lipolysis was promoted by hormones, proin flammatory cytokines, and lipidmobilizing factor. 21 One inter esting finding of lipid metabolism in cancer patients is fat brown ing. White adipose tissue cells convert to brown adipose tis suelike cells (beige cells) during cancerassociated cachexia, similar to the mechanism in cold environments. 22 The abun dant mitochondrial components of beige cells produce heat (thermogenesis) from ATP synthesis through increased un coupling protein1. 17 Fat browning in cancerassociated ca chexia represents imbalance of homeostasis and contributes to catabolic wasting unlike normal physiologic conditions.
IMPACT OF MALNUTRITION ON TREATMENT OUTCOMES IN CANCER PATIENTS
Although the stage and type of cancer and the response to chemotherapy are the most important prognostic factors, many studies have reported that patients who maintained weight gain presented better prognosis than those who did not. Mal nutrition is associated with longer hospital stay and higher rate of admission, delayed wound healing, deterioration of the immune system, and cancerassociated death. 2325 An impor tant association beyond just cause and effect has been eluci dated between malnutrition and aggravation of the disease. In a multicenter study investigating the prevalence of malnutri tion in patients during cancer treatment, old age, hospital stay, and metastasis showed an association with malnutrition. More over, malnutrition was associated with higher infection rate and longer hospital stay; 26 therefore, mere focus on increasing the weight of cancer patients does not affect the patient' s clini cal prognosis positively.
Sarcopenia in patients with cachexia has recently been not ed for contributing to poor prognosis in cancer patients. In a study that investigated prognosis of patients with cholangio www.irjournal.org carcinoma after major surgery, preoperative sarcopenia was associated with longer hospital stay, higher rate of liver failure, and higher postoperative infection rate. 27 Sarcopenia showed positive association with increased toxicity from chemothera py and faster tumor progression in patients with metastatic breast cancer, 28 and was related to lower survival rate. In a ret rospective study analyzing 229 stage III colon cancer patients, one standard deviation decrement of the psoas muscle mass index was related to an increased hazard of overall mortality in multivariate analysis. 29 Likewise, in a prospective study of patients with foregut cancer treated with neoadjuvant chemo therapy, loss of skeletal muscle mass was a predictor of reduced survival rate. 30 Several other studies of different cancer types reported that sarcopenia adversely affected the prognosis as sociated with cancer treatment and was associated with com plications.
The quality of social, psychological, and physical life can be greatly reduced because of the cancer pathology itself. The nutritional status of a cancer patient is influenced by the qual ity of life, because weight loss and decreased appetite are sig nificantly related to the quality of life. 31, 32 However, the poor quality of life in cancer patients is not solved simply by improv ing the nutritional status. A prospective randomized control trial showed that dietary intervention involving regular nutri tional counseling in patients with solid tumor during chemo therapy was not significantly related to a better quality of life as compared to the control. The results were consistent even if the patients had better nutritional status through nutritional counseling. The quality of life considerably improved in pa tients with significant tumor regression. 33 These results show that the relationship between cancer, malnutrition, and quali ty of life is complex.
NUTRITIONAL SCREENING AND ASSESSMENT IN CANCER PATIENTS
Assessing weight loss in cancer patients has been used since long as the simplest and most effective way to determine mal nutrition. Although BMI can be disturbed by ascites and body edema, many studies showed that BMI and unintended weight loss were the methods used to monitor malnutrition in patients and predict poor prognosis. Even though various nutritional assessment tools have been introduced and actively used, BMI still plays an important role. A study investigating 3,779 patients with colorectal cancer, between 1972 and 2017, revealed that the underweight group showed a significantly worse overall survival rate as compared to the normal weight group in stage III and IV cancer patients. More than 10% of weight reduction from prediagnosis to postdiagnosis showed a significant re lation with poorer overall survival. 34 Moreover, in a prospec tive study analyzing 82 metastatic breast cancer patients from 2011 to 2012, overweight patients showed a significant associ ation with lower rate of cancer mortality as compared to the normal weight patients. 35 Excessive nutrition is not recommen ded when considering the overall disease mortality including metabolic diseases. Furthermore, the prognosis is worse in overweight patients when there is accompanied muscle loss. Thus, it is obvious that simply maintaining the weight could play a protective role against cancer mortality.
Traditionally, serum concentrations of liver proteins, such as albumin, have been associated with the nutritional status of patients. Therefore, a lack of these proteins indicated under nourishment and was used as an indicator of active nutrition al support. 36 However, since albumin has a long halflife and is inhibited by inflammatory cytokines including TNFα and IL 6, which are elevated in cancer patients, it cannot be an imme diate and accurate indicator of malnutrition. 37 Nowadays, instead of using only 1 specific parameter to eval uate the patient, several factors are combined to assess the nutritional risk and evaluate the nutritional status. The Malnu trition Universal Screening Tool, Nutrition Risk Screening 2002, Mini Nutritional Assessment Short Form, and Malnutrition Screening Tool are validated and widelyused nutritional risk screening tools. 38 The purpose of nutritional risk screening is to emphasize the importance of nutritional support and pro mote early intervention to ultimately prevent poor outcomes due to malnutrition. Therefore, these screening tests should be easy to apply and interpret. Although they have different tar get patients, all the screening tools use parameters of BMI, weight change, accompanying disease, and degree of food intake. 39 The strategy for screening nutritional risk in cancer patients should adopt an individualized strategy for each medical insti tution considering the applicability of each tool. Although there is a lack of clear evidence eliciting the clinical benefits of nutri tional screening tools in cancer patients, no studies have proved the inefficacy of nutritional risk screening tools. 4042 In fact, there are certain benefits of screening for nutritional risk depending on the type and treatment of cancers. Therefore, the European Society for Clinical Nutrition and Metabolism (ESPEN) guide line recommends that there should be regular evaluation of nutritional intake, weight change, and BMI, that starts during cancer diagnosis and is repeated depending on the stability of www.irjournal.org the clinical situation. 39 If the patient is predisposed to have a nutritional risk, an as sessment of the patient' s nutritional status must be performed. Comprehensive nutritional assessment provides an objective goal for individualized nutritional care of the patients, ultimate ly improving the clinical outcomes by protecting the patients from treatment complications, and improving both the treat ment outcomes and quality of life. Therefore, the nutritional assessment of cancer patients should be repeated periodical ly, and not just once. There are many nutritional assessment tools used in researches and clinical practice. Although each nutritional assessment tool varies slightly, most tools consist of the patient' s medical history, food intake, physical activity level, weight change, other anthropometric measures, and laboratory test results. 43 Among the various tools available, the patientgeneratedsubjective global assessment (PGSGA) has been developed specifically for cancer patients. PGSAG is a tool that evaluates the clinical aspects, including physical examination and accompanying diseases, and confirms the change in the patient' s weight or dietary intake, presence or absence of gastrointestinal symptoms that may affect the di etary intake, and expresses a numerical score. 44 The start and posttreatment followup of nutritional intervention are based on this score. PGSGA is a valid and dependable tool that pro vides a reference to identify and classify the nutritional state of a cancer patient. Nutrition Risk Index is another commonly used assessment tools. 45, 46 Reduced muscle mass can be mea sured objectively using dual Xray absorptiometry, CT scans, or bioimpedance analysis (Table 1) .
NUTRITIONAL INTERVENTIONS
When a patient is diagnosed with cancer for the first time, the doctor should pay special attention to nutrition to prevent the patient from following detrimental diets. Doctors, as scientists, are naturally alert towards nonevidencebased treatments and excessive dietary imbalances, such as fad diets, that have a negative impact on the financial state as well as on the clini cal prognosis. A fad diet is an alternative medicine comprising of extremely high or low intake of certain foods, which will most likely result in nutritional imbalance. Furthermore, there is no strong evidence supporting the beneficial effects of the fad diets on cancer treatment. 39 Cancer patients are mentally vulnerable and tend to be obsessed with food control, and thus the patient could actively intervene in the cancer treat ment process. Hence, doctors treating cancer should under stand the characteristics of these patients and implement ap propriate interventions. Nutritional counseling and diet advice are therefore very important in cancer patients at nutritional risk during diagnosis, and these can be conducted from 3 per spectives. First, the amount of food consumed should be in creased. Second, the composition of the food should be bal anced along with highenergy intake from a nutritional point of view. Third, nutritional supplements that can be ingested orally should be considered. 42 Cochrane review reported that nutritional counseling had a beneficial effect on improving the weight reduction and quality of life in patients with cancer by analyzing randomized controlled trials. 42 In addition to nu tritional counseling, there have been studies wherein patients who consumed oral nutritional supplements demonstrated 47 On the other hand, another metaanalysis showed that oral nutritional supplementation improved the quality of life of patients but did not reduce the mortality in cancer patients. 47 From the perspective of overcoming sarcopenia, highpro tein diets can be considered. Patients with acute or chronic diseases need 1.5 g/kg of protein per day, but one study found that 35% of cancer patients consumed fewer proteins than re quired. 48, 49 A randomized, controlled, doubleblind, parallel group designed study using experimental highprotein diet in cancer patients revealed that the highprotein diet group show ed significantly better muscle synthesis than the control group. 50 Although leucine is the most important amino acid in muscle synthesis, there are no consistent results showing that high doses of leucine will help prognosis in patients with cancer. Moreover, a recent experimental study showed that high level of leucine could induce tamoxifen resistance in estrogenre ceptor positive breast cancer patients. 51 Therefore, when using high dose of a specific nutrient, a thoughtful evaluation is nec essary. Glutamine is also considered a nutritional supplement for cancer patients. Glutamine is a nonessential amino acid that serves an important role in the metabolism and immune system. Glutamine levels are reduced in cancer patients be cause glutamine is used as the energy source by cancer cells. Glutamine supplementation is usually focused on preventing side effects that may occur during chemotherapy or radiother apy, especially in gastrointestinal mucosal protection. A pro spective study investigating the beneficial effect of a parenteral glutamine supplementation in 24 metastatic colorectal cancer patients during chemotherapy revealed that glutamine sup plementation was associated with a significant reduction in mucositis and ulceration of the upper gastrointestinal muco sa. 52 However, additional prospective studies are needed to determine the relationship between prognosis and glutamine supplementation in cancer patients and the effect of oral and intravenous glutamine.
Omega3 fatty acids can also be expected to provide nutri tional supplementation in cancer patients. Unlike omega6 fatty acids, omega3 fatty acids have antiinflammatory effects and do not promote angiogenesis. 53 Therefore, supplementing omega3 in cancer patients has the advantage of providing nutrition, especially fat, without stimulating tumor growth. In some studies, 54,55 omega3 supplementation was shown to help weight gain in cancer patients, while other systematic re view studies showed that there was unclear evidence of the beneficial effect of omega3 in improving cachexia in cancer patients. 56, 57 However, since the intake of omega3 fatty acids rarely causes serious adverse effects, the ESPEN guideline rec ommended supplementing omega3 fatty acids in cancer pa tients having weight loss. 39 
CONCLUSION
There is a lack of attention towards the nutritional status of cancer patients in clinical practice. However, monitoring and intervention of nutritional status not only affect the quality of life of the patient, but also the treatment response and clinical outcomes. Since no strategy particularly good at improving the nutritional status in cancer patients has yet been developed, it is important that individualized treatments be performed for each patient according to their nutritional assessment. More over, continuous vigilance regarding factors affecting nutri tional status in patients with cancer is necessary.
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